Loading...
Search for:
phase-1-clinical-trial--topic
0.009 seconds
Nanotechnology in diagnosis and treatment of coronary artery disease
, Article Nanomedicine ; Volume 11, Issue 5 , 2016 , Pages 513-530 ; 17435889 (ISSN) ; Zare, H ; Bakhshian Nik, A ; Yazdani, N ; Hamrang, M ; Mohamed, E ; Sahandi Zangabad, P ; Moosavi Basri, S. M ; Bakhtiari, L ; Hamblin, M. R ; Sharif University of Technology
Future Medicine Ltd
Abstract
Nanotechnology could provide a new complementary approach to treat coronary artery disease (CAD) which is now one of the biggest killers in the Western world. The course of events, which leads to atherosclerosis and CAD, involves many biological factors and cellular disease processes which may be mitigated by therapeutic methods enhanced by nanotechnology. Nanoparticles can provide a variety of delivery systems for cargoes such as drugs and genes that can address many problems within the arteries. In order to improve the performance of current stents, nanotechnology provides different nanomaterial coatings, in addition to controlled-release nanocarriers, to prevent in-stent restenosis....
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
, Article Cancer Cell International ; Volume 20, Issue 1 , September , 2020 ; Tafsiri, E ; Cho, W. C. S ; Ghaemi, A ; Sharif University of Technology
BioMed Central Ltd
2020
Abstract
Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called "adoptive cell transfer", or ACT, process. Construction of allogeneic T-cells is dependent on the employment of a gene-editing tool to modify donor-extracted T-cells and prepare them to specifically act against tumor cells with enhanced function and durability and least side-effects. In this context, CRISPR technology can be used to produce universal T-cells, equipped with recombinant T cell...
Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes
, Article AAPS Journal ; Volume 19, Issue 3 , 2017 , Pages 652-668 ; 15507416 (ISSN) ; Fathe, K. R ; Brunaugh, A ; Ferrati, S ; Li, S ; Montenegro Nicolini, M ; Mousavikhamene, Z ; McConville, J. T ; Prausnitz, M. R ; Smyth, H. D. C ; Sharif University of Technology
Springer New York LLC
2017
Abstract
Biologic products are large molecules such as proteins, peptides, nucleic acids, etc., which have already produced many new drugs for clinical use in the last decades. Due to the inherent challenges faced by biologics after oral administration (e.g., acidic stomach pH, digestive enzymes, and limited permeation through the gastrointestinal tract), several alternative routes of administration have been investigated to enable sufficient drug absorption into systemic circulation. This review describes the buccal, sublingual, pulmonary, and transdermal routes of administration for biologics with relevant details of the respective barriers. While all these routes avoid transit through the...